Swiss Patient Leader Insights - Can more be done for Market & Patient Access of DHTs? | Jennifer Woods

How Ready Is Swiss Healthcare for Digital Transformation? From Market Access to Adoption

How ready is Swiss healthcare for digital transformation? Prof. Alfred Angerer from ZHAW joins us to discuss the key findings from the latest Digital Health Report and what they mean for patients, hospitals, doctors, insurance companies, and technology developers - startups, pharma, and medtech. Tune in for a clear-eyed look at the opportunities, barriers, and future of digital health in Switzerland. We also explore whether the health technology assessment (HTA) criteria used in market access are aligned (or not) with the factors that drive successful adoption of digital health solutions. Wer es lieber elektronisch mag: Hier kostenlos das PDF runterladen|  If you prefer a PDF of the Digital Health Report, download it for free here:  https://www.mwv-berlin.de/meldung/!/id/593   GET IN TOUCH: Feedback? We’re listening. Send us a message on LinkedIn:  https://linkedin.com/in/gurmitsandhu [https://www.linkedin.com/in/gurmitsandhu]   | https://linkedin.com/in/angelina-rau [https://linkedin.com/in/angelina-rau] Share your experience, feedback, “pain points”  or success with market access & reimbursement of digital health technology #medtech  #meddevice :  on the comments section below or DM us on LinkedIn Do you know someone who would be a great guest for us to interview? Let us know via LinkedIn | Topics that you want us to focus on. Drop us a comment below! What to Read:   Reimbursement guide on digital health applications within the Swiss healthcare system | Created in collaboration with experts in insurance, law, pharma, and industry including Angelina Rau | Free access, in Eng & De => https://swisshealthcarestartups.com/en/reimbursement-guide [https://swisshealthcarestartups.com/en/reimbursement-guide]  Kohler, Stefan / Rau, Angelina, Vergütung digitaler Gesundheitsanwendungen in der Schweiz, Life Sciences Recht Stämpfli, LSR 1/2023, S. 13-22 [https://lsr.recht.ch/de/artikel/02lsr0123auf/vergutung-von-digitalen-gesundheitsanwendungen-diga-der-schweiz], Januar 2023        Sandhu G, Mohamed Ghazali IM, Laurenzi E, Miho E. PP22 A Dashboard To Support The Value Assessment Of Digital Health Technologies F...

🎙️ The Adoption Gap: What the AI for IMPACTS Framework Means for Swiss Market Access

In this episode, co-hosts Gurmit and Angelina speak with Dr. Christine Jacob, Digital Strategist, Health Tech Researcher, Lecturer at FHNW, and internationally recognised expert in technology adoption in healthcare. With over 20 years of industry experience exploring how social, organisational and technical factors shape the acceptance of digital health tools, Christine brings a unique, science-based perspective on how innovation truly lands in healthcare. Our conversation explores the second half of the reimbursement journey: Adoption. While previous episodes focused on the Assessment phase, such as evaluating digital health technologies through tools like Gurmit’s Value Assessment Dashboard (VAD), this episode turns to what happens after assessment — ensuring technologies are actually understood, accepted, and implemented in real-world care settings. Together, we unpack: ·         The core “pain points” slowing adoption of digital health solutions today ·         The benefits that would emerge if these adoption barriers disappeared ·         Christine’s latest research: The AI for IMPACTS Framework – Why she developed it – How it helps organisations navigate responsible, user-centered AI adoption – Where it can be applied across Swiss healthcare settings ·         How this framework complements existing assessment tools — and where it can support better, evidence-based decision-making for Swiss market access We also reflect on how the Swiss healthcare system can better integrate digital technologies, from hospitals and insurers to patients and clinicians — and how structured adoption frameworks can support more confident, transparent, and scalable digital innovation. As always, opinions expressed are those of our guest. For more information, listeners are encouraged to consult official sources and Christine’s recent publication on the AI for IMPACTS Framework. Sources:  Jacob C, Brasier N, Laurenzi E, Heuss S, Mougiakakou S, Cöltekin A, Peter M AI for IMPACTS Framework for Evaluating the Long-Term Real-World Impacts of AI-Powered Clinician Tools: Systematic Review and Narrative Synthesis. J Med Internet Res 2025;27:e67485 URL: https://www.jmir.org/2025/1/e67485 [https://www.jmir.org/2025/1/e67485]  DOI: 10.2196/67485   GET IN TOUCH: Feedback? We’re listening. Send us a message on LinkedIn:  https://linkedin.com/in/gurmitsandhu [https://www.linkedin.com/in/gurmitsandhu]   | https://linkedin.com/in/angelina-rau [https://linkedin.com/in/angelina-rau] Share your experience, feedback, “pain points”  or success with market access & reimbursement of digital health technology #medtech  #meddevice :  on the comments section below or DM us on LinkedIn Do you know someone who would be a great guest for us to interview? Let us know via LinkedIn | Topics that you want us to focus on. Drop us a comment below! What to Read:   Reimbursement guide on digital health applications within the Swiss healthcare system | Created in collaboration with experts in insurance, law, pharma, and industry including Angelina Rau | Free access, in Eng & De => https://swisshealthcarestartups.com/en/reimbursement-guide [https://swisshealthcarestartups.com/en/reimbursement-guide]  Kohler, Stefan / Rau, Angelina, Vergütung digitaler Gesundheitsanwendungen in der Schweiz, Life Sciences Recht Stämpfli, LSR 1/2023, S. 13-22 [https://lsr.recht.ch/de/artikel/02lsr0123auf/vergutung-von-digitalen-gesundheitsanwendungen-diga-der-schweiz], Januar 2023        Sandhu G, Mohamed Ghazali IM, Laurenzi E, Miho E. PP22 A Dashboard To Support The Value Assessment Of Digital Health Technologies F...

Swiss Tariff System: Market Access for Digital Health Applications

In this episode (in Swiss German), host Angelina Rau sits down with Barbara Meier, attorney at law at VISCHER AG and expert in tariff and healthcare law, to unpack one of the most complex yet crucial topics for digital health innovators in Switzerland — reimbursement and tariffs. They discuss how Digital Health Applications (DiGAs) — software-based medical devices such as health apps or digital therapeutics — gain access to the Swiss healthcare system. Even when approved and recognized under compulsory health insurance (OKP), a DiGA can only be reimbursed if it fits into an appropriate reimbursement and tariff structure. Barbara explains Switzerland’s three main reimbursement “categories”: * Hospitals, inpatient and outpatient tariffs (like TARMED and the upcoming TARDOC) for services delivered by healthcare professionals, * and the MiGeL list, covering DiGAs provided directly to patients. Together, they explore how upcoming reforms, such as TARDOC, aim to modernize reimbursement for telemedicine and digital care — and why early collaboration between manufacturers and healthcare providers is essential for success. Whether you’re a startup founder, digital health manufacturer, or health policy professional, this episode offers clear insights on how to navigate tariff systems, secure reimbursement, and bring innovation into the Swiss healthcare landscape. GET IN TOUCH: Feedback? We’re listening. Send us a message on LinkedIn:  https://linkedin.com/in/gurmitsandhu [https://www.linkedin.com/in/gurmitsandhu]   | https://linkedin.com/in/angelina-rau [https://linkedin.com/in/angelina-rau] Share your experience, feedback, “pain points”  or success with market access & reimbursement of digital health technology #medtech  #meddevice :  on the comments section below or DM us on LinkedIn Do you know someone who would be a great guest for us to interview? Let us know via LinkedIn | Topics that you want us to focus on. Drop us a comment below! What to Read:   Reimbursement guide on digital health applications within the Swiss healthcare system | Created in collaboration with experts in insurance, law, pharma, and industry including Angelina Rau | Free access, in Eng & De => https://swisshealthcarestartups.com/en/reimbursement-guide [https://swisshealthcarestartups.com/en/reimbursement-guide]  Kohler, Stefan / Rau, Angelina, Vergütung digitaler Gesundheitsanwendungen in der Schweiz, Life Sciences Recht Stämpfli, LSR 1/2023, S. 13-22 [https://lsr.recht.ch/de/artikel/02lsr0123auf/vergutung-von-digitalen-gesundheitsanwendungen-diga-der-schweiz], Januar 2023        Sandhu G, Mohamed Ghazali IM, Laurenzi E, Miho E. PP22 A Dashboard To Support The Value Assessment Of Digital Health Technologies F...

Invitation to participate in an online survey: Gap Analysis on Swiss Assessment of DHTs

Are you a Switzerland-based stakeholder interested in the market access assessment of digital health technologies for the Swiss market? We value your input on how digital health technologies (DHTs) are currently assessed for market access (leading to reimbursement) in Switzerland — particularly by those without deep regulatory expertise.  Two webinars will be held in October 2025 to provide context for completing the survey and introduce the key themes behind our research. You can still complete this survey even if you don't attend a webinar. Later in 2026, we will be sharing the results of our study.  Survey link in English: https://forms.gle/7KxkNgsvQidWQkEy5 Link zur Umfrage auf Deutsch: https://forms.gle/bcChDitFKWddX2BK8  Join the webinar (optional) without registration. In English & Deutsch : Thursday 16th Oct 2025, 12 - 12.30 pm:  https://fhnw.zoom.us/j/66432766035 [https://fhnw.zoom.us/j/66432766035]  Monday 27th Oct 2025, 12 - 12.30 pm:  https://fhnw.zoom.us/j/66859461413 [https://fhnw.zoom.us/j/66859461413]  End of Survey: 31st Oct 2025 Vielen Dank, dass Sie sich die Zeit nehmen, uns Ihre Meinung zu unserer Gap-Analyse-Studie zu den Schweizer Kriterien für Wirksamkeit, Zweckmässigkeit und Wirtschaftlichkeit (WZW-Kriterien) im Vergleich zu den neueren Nutzenbewertungstools für digitale Gesundheitstechnologien mitzuteilen. Beispiele hierfür sind die Deutsche Digitale Gesundheits-Anwendung (DIGA) und das Value Assessment Dashboard (VAD). Im Allgemeinen werden diese Kriterien von Behörden für Health Technology Assessments (HTA) während der Marktzugangsphase des Lebenszyklus einer Gesundheitstechnologie verwendet. Die nachfolgende Phase ist in der Regel die Erstattungsphase. Ihr Feedback hilft uns dabei, Perspektiven aufzuzeigen, die oft nicht öffentlich zugänglich sind oder nicht erfasst werden. Es handelt sich um eine selbst finanzierte Studie für Schweizer Interessengruppen (Einwohner*innen und Bürger*innen), die sich für die Bewertung digitaler Gesundheitstechnologien für den Schweizer Markt interessieren. Wir planen, eine Zusammenfassung unserer Arbeit zu veröffentlichen. Details zur Umfrage siehe oben. Abgesehen von Ihrer E-Mail-Adresse erfassen wir keine weiteren personenbezogenen Daten. GET IN TOUCH: Feedback? We’re listening. Send us a message on LinkedIn:  https://linkedin.com/in/gurmitsandhu [https://www.linkedin.com/in/gurmitsandhu]   | https://linkedin.com/in/angelina-rau [https://linkedin.com/in/angelina-rau] Share your experience, feedback, “pain points”  or success with market access & reimbursement of digital health technology #medtech  #meddevice :  on the comments section below or DM us on LinkedIn Do you know someone who would be a great guest for us to interview? Let us know via LinkedIn | Topics that you want us to focus on. Drop us a comment below! What to Read:   Reimbursement guide on digital health applications within the Swiss healthcare system | Created in collaboration with experts in insurance, law, pharma, and industry including Angelina Rau | Free access, in Eng & De => https://swisshealthcarestartups.com/en/reimbursement-guide [https://swisshealthcarestartups.com/en/reimbursement-guide]  Kohler, Stefan / Rau, Angelina, Vergütung digitaler Gesundheitsanwendungen in der Schweiz, Life Sciences Recht Stämpfli, LSR 1/2023, S. 13-22 [https://lsr.recht.ch/de/artikel/02lsr0123auf/vergutung-von-digitalen-gesundheitsanwendungen-diga-der-schweiz], Januar 2023        Sandhu G, Mohamed Ghazali IM, Laurenzi E, Miho E. PP22 A Dashboard To Support The Value Assessment Of Digital Health Technologies F...

Swiss Patient Leader Insights - Can more be done for Market & Patient Access of DHTs? | Jennifer Woods

Jennifer Woods, Swiss Patient Leader and PPI partner, shares how Switzerland can strengthen patient access to digital health technologies: from usability and patient-reported outcomes/experience measures (PROMs & PREMs) to data privacy & security, value-based care, and the daily burden of illness. Beyond highlighting the gaps, she points to solutions — such as integrating patient voices earlier and systematically in HTA processes and aligning market access with real-world patient needs. Jennifer is a Patient Partner for the Swiss Academy of Medical Sciences’ Coordination Platform for Clinical Research (CPCR) and the National Data Stream (NDS) LUCID. She is also an EUPATI Patient Expert and Carney Complex Advocate. 👉 Swiss German summary at the end. PPI Patient & Public Involvement  https://www.samw.ch/en.html [https://www.samw.ch/en.html]  https://sphn.ch/network/projects/project-page_nds_lucid/ [https://sphn.ch/network/projects/project-page_nds_lucid/]  GET IN TOUCH: Feedback? We’re listening. Send us a message on LinkedIn:  https://linkedin.com/in/gurmitsandhu [https://www.linkedin.com/in/gurmitsandhu]   | https://linkedin.com/in/angelina-rau [https://linkedin.com/in/angelina-rau] Share your experience, feedback, “pain points”  or success with market access & reimbursement of digital health technology #medtech  #meddevice :  on the comments section below or DM us on LinkedIn Do you know someone who would be a great guest for us to interview? Let us know via LinkedIn | Topics that you want us to focus on. Drop us a comment below! What to Read:   Reimbursement guide on digital health applications within the Swiss healthcare system | Created in collaboration with experts in insurance, law, pharma, and industry including Angelina Rau | Free access, in Eng & De => https://swisshealthcarestartups.com/en/reimbursement-guide [https://swisshealthcarestartups.com/en/reimbursement-guide]  Kohler, Stefan / Rau, Angelina, Vergütung digitaler Gesundheitsanwendungen in der Schweiz, Life Sciences Recht Stämpfli, LSR 1/2023, S. 13-22 [https://lsr.recht.ch/de/artikel/02lsr0123auf/vergutung-von-digitalen-gesundheitsanwendungen-diga-der-schweiz], Januar 2023        Sandhu G, Mohamed Ghazali IM, Laurenzi E, Miho E. PP22 A Dashboard To Support The Value Assessment Of Digital Health Technologies F...